CTRI/2011/12/002256尚未招募未知
A randomized, open-label, single dose, two-period, within formulation crossover study of Coartem to evaluate the bioequivalence between a novel single 4-in-1 tablet and a dose of four individual tablets and between a novel single 3-in-1 tablet and a dose of three individual tablets in healthy volunteers
ovartis Healthcare Pvt Ltd0 个研究点目标入组 120 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Healthy subjects
- •2. Female subjects must be of non-child bearing potential
- •3. Subjects must weigh at least 50kg & their BMI 18 to 30kg/m2 for participation
排除标准
- •1. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
- •2. Smokers
- •3. Laboratory screening tests within normal ranges.
- •4. Pregnant or nursing (lactating) women,
研究者
相似试验
已完成
不适用
Bioavailability study between Pirfenidone ER tablet 1200 mg and PIRFENEX (pirfenidone) 200 mg tablet in healthy human subjectsCTRI/2021/09/036729Cipla Ltd India60
进行中（未招募）
不适用
A research study to find out whether a product to be tested (salmeterol xinafoate HFA pMDI 25 µg per actuation, manufactured by Cipla Ltd, India) is equivalent to the already existing formulation (salmeterol xinafoate HFA pMDI 25 µg per actuation (Serevent Evohaler™), supplied by Allen and Hanburys, UK) when administered by a volumatic spacer device to children with asthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2014-001946-10-BGCipla Ltd.80
已完成
不适用
An open-label, single-dose, randomized, two-period, two-treatment, two-sequence, crossover, oral dissolution study to assess sugar free and sugared cetylpyridinium chloride (CPC-1.4mg) and benzocaine (10mg) lozenges in healthy subjectsNL-OMON51112Reckitt Benckiser Healthcare (UK) Limited (RB)16
进行中（未招募）
1 期
Clinical trial in Healthy Volunteers to test Valsartan PharmacokineticsHypertensionEUCTR2016-004323-23-Outside-EU/EEAovartis86
已完成
1 期
A study to compare the concentrations of valsartan in plasma when valsartan is taken as solution formulation and as tablet formulation.CTRI/2010/091/001094ovartis Healthcare Private Limited Andhra Pradesh India30